BVF Inc. IL Sells 116,352 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

BVF Inc. IL cut its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 9.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,073,755 shares of the biopharmaceutical company's stock after selling 116,352 shares during the quarter. Agios Pharmaceuticals makes up about 1.2% of BVF Inc. IL's holdings, making the stock its 20th biggest position. BVF Inc. IL owned approximately 1.88% of Agios Pharmaceuticals worth $35,284,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in shares of Agios Pharmaceuticals by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 5,631,321 shares of the biopharmaceutical company's stock worth $185,045,000 after buying an additional 85,339 shares during the last quarter. Fisher Asset Management LLC boosted its position in Agios Pharmaceuticals by 12.3% in the fourth quarter. Fisher Asset Management LLC now owns 960,661 shares of the biopharmaceutical company's stock worth $31,567,000 after purchasing an additional 105,333 shares during the last quarter. ArrowMark Colorado Holdings LLC grew its stake in Agios Pharmaceuticals by 3.9% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 917,420 shares of the biopharmaceutical company's stock valued at $30,146,000 after purchasing an additional 34,689 shares during the period. Caligan Partners LP increased its position in shares of Agios Pharmaceuticals by 8.0% during the 4th quarter. Caligan Partners LP now owns 626,280 shares of the biopharmaceutical company's stock valued at $20,580,000 after purchasing an additional 46,563 shares during the last quarter. Finally, Northern Trust Corp raised its stake in shares of Agios Pharmaceuticals by 0.9% during the 4th quarter. Northern Trust Corp now owns 595,480 shares of the biopharmaceutical company's stock worth $19,567,000 after purchasing an additional 5,372 shares during the period.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. StockNews.com upgraded shares of Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Thursday, May 1st. HC Wainwright assumed coverage on shares of Agios Pharmaceuticals in a research report on Monday, February 24th. They set a "buy" rating and a $58.00 target price for the company. Finally, Scotiabank lowered their price target on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating on the stock in a report on Friday, May 2nd. Five research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $56.00.

Agios Pharmaceuticals Stock Performance

AGIO stock traded down $0.15 during midday trading on Wednesday, reaching $28.17. 543,940 shares of the company's stock traded hands, compared to its average volume of 699,458. Agios Pharmaceuticals, Inc. has a 52 week low of $23.42 and a 52 week high of $62.58. The company has a 50-day moving average price of $29.45 and a two-hundred day moving average price of $37.52. The firm has a market capitalization of $1.63 billion, a PE ratio of 2.48 and a beta of 0.77.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) EPS for the quarter, topping the consensus estimate of ($1.80) by $0.25. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. The business had revenue of $8.73 million during the quarter, compared to the consensus estimate of $9.86 million. As a group, analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Jacqualyn A. Fouse sold 7,497 shares of the stock in a transaction on Thursday, April 10th. The stock was sold at an average price of $25.90, for a total value of $194,172.30. Following the sale, the director now owns 149,220 shares in the company, valued at approximately $3,864,798. This trade represents a 4.78 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 4.93% of the stock is currently owned by insiders.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.